Therapeutic Controversies Tumor Necrosis Factor α Inhibitors in Ankylosing Spondylitis

被引：5

作者：

Song, I. H. ^{[2
]}

Maksymowych, W. P. ^{[1
]}

机构：

[1] Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada

[2] Charite, D-13353 Berlin, Germany

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2012年 / 38卷 / 03期

关键词：

INF-alpha inhibitor; Ankylosing spondylitis; Efficacy; Immunogenicity; Extraarticular manifestations; Uveitis; Magnetic resonance imaging; Radiographic progression; PLACEBO-CONTROLLED TRIAL; EARLY AXIAL SPONDYLOARTHRITIS; ANTI-TNF THERAPY; SOCIETY CLASSIFICATION CRITERIA; ACTIVE INFLAMMATORY LESIONS; RESONANCE-IMAGING PREDICT; WHOLE-BODY MRI; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; CLINICAL-RESPONSE;

D O I：

10.1016/j.rdc.2012.08.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Tumor necrosis factor a inhibitors (TNF blockers) have revolutionized the treatment of patients with ankylosing spondylitis. Despite clinical efficacy, there are questions and controversies treating rheumatologists face, which this review discusses: whether there are specific indications for specific TNF blockers; whether the dose of TNF blockers can be decreased; whether immunogenicity plays a role; what the role of residual active inflammation on MRI might be; and whether there is a window of opportunity to treat patients with ankylosing spondylitis and prevent radiographic progression. This article also summarizes evidence for switching between TNF blockers and addresses the question of malignancies.

引用

页码：613 / +

页数：22

共 50 条

[41] Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment With Tumor Necrosis Factor Inhibitors
Maas, Fiona
Arends, Suzanne
Brouwer, Elisabeth
Essers, Ivette
van der Veer, Eveline
Efde, Monique
van Ooijen, Peter M. A.
Wolf, Rinze
Veeger, Nic J. G. M.
Bootsma, Hendrika
Wink, Freke R.
Spoorenberg, Anneke
ARTHRITIS CARE & RESEARCH, 2017, 69 (07) : 1011 - 1019
[42] Gender Differences in Ankylosing Spondylitis: Men Derive Greater Benefit from Tumor Necrosis Factor Alpha Inhibitors
Mandal, Jennifer
Ward, Michael M.
Weisman, Michael
Simard, Jillian
Brown, Matthew A.
Lee, MinJae
Rahbar, Mohammad H.
Reveille, John D.
Gensler, Lianne S.
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[43] TREATMENT OF ANKYLOSING SPONDYLITIS WITH TUMOR NECROSIS FACTOR-ALPHA INHIBITORS LOWERS THE RISK OF RENAL FUNCTION DECLINE
Lee, S. J.
Lee, J. S.
Cha, U. C.
Nam, E. J.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 731 - 731
[44] Tumor necrosis factor: Biology and therapeutic inhibitors
Papadakis, KA
Targan, SR
GASTROENTEROLOGY, 2000, 119 (04) : 1148 - 1157
[45] Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis
Wang, Runsheng
Dasgupta, Abhijit
Ward, Michael M.
JOURNAL OF RHEUMATOLOGY, 2018, 45 (04) : 481 - 490
[46] EVALUATION OF THE EFFICACY OF INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA FOR PATIENTS WITH ANKYLOSING SPONDYLITIS IN REAL CLINICAL PRACTICE.
Rozochkina, E.
Koltsova, E.
Murtazalieva, D.
Zhilyaev, E.
Koshkarova, E.
Lukina, G.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1511 - 1512
[47] Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing Spondylitis
Perpetuo, Ines P.
Raposeiro, Rita
Caetano-Lopes, Joana
Vieira-Sousa, Elsa
Campanilho-Marques, Raquel
Ponte, Cristina
Canhao, Helena
Ainola, Mari
Fonseca, Joao E.
PLOS ONE, 2015, 10 (12):
[48] Treatment of ankylosing spondylitis via tumor necrosis factor-alpha inhibition
Christopher T. Ritchlin
Current Rheumatology Reports, 2002, 4 (6) : 497 - 497
[49] Drug Insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis
Cailin Henderson
John C Davis
Nature Clinical Practice Rheumatology, 2006, 2 : 211 - 218
[50] Drug Insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis
Henderson, C
Davis, JC
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (04): : 211 - 218

← 1 2 3 4 5 →